Scarica l'app Stockscreener
3.40
1.49%
0.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.35
Aprire:
$3.35
Volume 24 ore:
640.92K
Relative Volume:
0.85
Capitalizzazione di mercato:
$651.78M
Reddito:
$12.99M
Utile/perdita netta:
$-74.39M
Rapporto P/E:
-7.7273
EPS:
-0.44
Flusso di cassa netto:
$-78.92M
1 W Prestazione:
-0.29%
1M Prestazione:
+7.26%
6M Prestazione:
+2.72%
1 anno Prestazione:
-6.08%
Intervallo 1D:
$3.33
$3.4065
Intervallo di 1 settimana:
$3.305
$3.55
Portata 52W:
$2.705
$4.725
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Nome
Arbutus Biopharma Corp
Settore
Industria
Telefono
604-419-3200
Indirizzo
701 VETERANS CIRCLE, WARMINSTER, PA
Confronta ABUS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
3.40 | 642.19M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-02-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-02-25 | Iniziato | Jefferies | Hold |
| 2020-12-17 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-27 | Ripresa | JMP Securities | Mkt Outperform |
| 2020-07-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-03-06 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | Iniziato | Robert W. Baird | Outperform |
| 2020-02-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | Reiterato | B. Riley FBR | Buy |
| 2019-10-04 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2018-10-12 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-06 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | Ripresa | Chardan Capital Markets | Buy |
| 2018-03-19 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | Reiterato | Wedbush | Outperform |
| 2016-12-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
Mostra tutto
Arbutus Biopharma Corp Borsa (ABUS) Ultime notizie
XTX Topco Ltd Increases Position in Arbutus Biopharma Corporation (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corporation stock outlook for YEARWeekly Growth Portfolio Performance Summary - Newser
Forecasting Arbutus Biopharma Corporation price range with options dataStrong Buy Opportunity with Volume Support - Newser
Is Arbutus Biopharma Corporation stock ready for a breakoutStrategy Playbook for Risk Controlled Trades - Newser
Is Arbutus Biopharma Corporation stock reversal real or fakeBuy/Sell Zone Confirmation Technical Analysis - Newser
News impact scoring models applied to Arbutus Biopharma CorporationMomentum-Based Prediction for Quick Returns - Newser
Arbutus Biopharma Corporation stock momentum explainedTrading Watchlist with Real Time Filters - Newser
Why Arbutus Biopharma Corporation stock attracts strong analyst attentionSafe Entry Screening with Data Backed Analysis - Newser
How to integrate Arbutus Biopharma Corporation into portfolio analysis toolsTrade Setup Builder with Custom Alerts - Newser
What moving averages say about Arbutus Biopharma CorporationFree Smart Money Tracking Signal Generator - Newser
Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Position Decreased by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Applying big data sentiment scoring on Arbutus Biopharma CorporationTechnical Safety Zone Pattern Recognition - Newser
Arbutus Biopharma (NASDAQ:ABUS) Stock Rating Upgraded by Wall Street Zen - Defense World
Is now a turning point for Arbutus Biopharma CorporationFree Alpha Focused Technical Trade Signals - Newser
Is Arbutus Biopharma Corporation stock entering bullish territoryFree Community Strategy With High Win Rate - Newser
When is the best time to buy Arbutus Biopharma Corporation stockPortfolio Safety Metrics and Return Analysis - Newser
Arbutus Biopharma Returns to Profitability as It Regains Global Rights to Lead Hepatitis B Drug - MyChesCo
What risks could impact Arbutus Biopharma Corporation stock performanceLong Term Stock Growth Plan Suggestions - Newser
Arbutus: Q2 Earnings Snapshot - Connecticut Post
Arbutus Biopharma Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Arbutus Biopharma earnings beat by $0.05, revenue topped estimates - Investing.com
Arbutus Biopharma Reports Q2 Earnings of $2.523mln, Revenue of $10.739mln, EPS of $0.01 - AInvest
Arbutus Biopharma Corp Reports Q2 2025 Earnings: EPS of $0.01 an - GuruFocus
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Real time social sentiment graph for Arbutus Biopharma CorporationHigh Return Strategy with Low Risk - Newser
Arbutus Biopharma (ABUS) Projected to Post Earnings on Thursday - Defense World
Arbutus Biopharma Corporation stock trendline breakdownMarket Timing Strategy with Technical Filters - Newser
What are the latest earnings results for Arbutus Biopharma CorporationBuild a diversified portfolio for steady growth - Jammu Links News
What are the technical indicators suggesting about Arbutus Biopharma CorporationTriple-digit returns - Jammu Links News
What data driven models say about Arbutus Biopharma Corporation’s futureShort Term High Yield Stock Tips for Active Traders - beatles.ru
Bank of New York Mellon Corp Decreases Holdings in Arbutus Biopharma Corporation (NASDAQ:ABUS) - Defense World
Technical analysis overview for Arbutus Biopharma Corporation stockFree Buy Low Sell High Stock Watch - Newser
Arbutus Biopharma Corporation Recovery Hinges on Volume BreakoutSecure Return Focused Investment Plan Released - metal.it
Published on: 2025-07-30 00:59:28 - Newser
Will breakout in Arbutus Biopharma Corporation lead to full recoveryFree Reliable Chart-Based Trade Entries - Newser
Published on: 2025-07-28 23:59:46 - beatles.ru
What catalysts could drive Arbutus Biopharma Corporation stock higher in 2025Consistently exceptional gains - Jammu Links News
Arbutus Biopharma Corp expected to post a loss of 5 cents a shareEarnings Preview - TradingView
Does Arbutus Biopharma Corporation stock perform well during market downturnsRapid market gains - jammulinksnews.com
Arbutus Biopharma Corp Azioni (ABUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):